Engineered cascade components and cascade complexes
Inventors
Cameron, Peter Sean • Klompe, Sanne Eveline • Sternberg, Samuel Henry
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present disclosure provides engineered Class 1 Type I CRISPR-Cas (Cascade) systems that comprise multi-protein effector complexes, nucleoprotein complexes comprising Type I CRISPR-Cas subunit proteins and nucleic acid guides, polynucleotides encoding Type I CRISPR-Cas subunit proteins, and guide polynucleotides. Also, disclosed are methods for making and using the engineered Class 1 Type I CRISPR-Cas systems of the present invention.
Core Innovation
The disclosed subject matter describes engineered Class 1 Type I CRISPR-Cas effector complexes, including Cascade, to target nucleic acid target sequences and modulate transcription at regulatory elements. In certain embodiments, transcription activation is achieved by recruiting a transcription activation factor using a Cascade-VP64/TA approach, and transcriptional repression is achieved using a Cascade-KRAB approach. The targeting is described relative to regulatory element locations such as TSS.
The disclosure also describes Type I CRISPR-Cas3 deletion strategies for 3′ to 5′ long-range genomic deletions. In one strategy, a single Cascade with a stop via dCas9/NATNA is used, and in another strategy two Cascades with two stop sites are used to enable the described long-range deletions. The concept is presented as controlling the deletion outcome using combinations of Cascade components and stop elements.
Extensive embodiments are described for Cascade complex design, including engineered Cas subunit proteins such as Cas5 and Cas7 within the Class 1 Type I CRISPR-Cas effector complex and fusion concepts involving Cas8 with FokI linked by a linker polypeptide. Guide polynucleotides are used to bind nucleic acid target sequences, and PAM constraints and interspacer distance concepts are described to define target positioning for the engineered system.
Claims Coverage
The claim coverage centers on a human stem cell engineered with two engineered Class 1 Type I CRISPR-Cas effector complexes, each comprising Cas5 and Cas7 subunit proteins and a Cas8-FokI fusion connected by a linker polypeptide, with guide polynucleotides targeting respective nucleic acid target sequences. The PAMs of the two target sequences have a defined interspacer distance, and the cell is outside of a human body.
Two engineered Class 1 Type I CRISPR-Cas effector complexes in a human stem cell
A human stem cell comprises a first engineered Class 1 Type I CRISPR-Cas effector complex with a first Cas5 subunit protein and a first Cas7 subunit protein, and a second engineered Class 1 Type I CRISPR-Cas effector complex with a second Cas5 subunit protein and a second Cas7 subunit protein.
Cas8-FokI fusion connected by a covalent linker polypeptide
Each engineered complex includes a fusion protein comprising a Cas8 subunit protein and a FokI, wherein the Cas8 subunit protein is covalently connected to the FokI by a linker polypeptide.
Defined PAM interspacer distance between first and second targets
A PAM of the first nucleic acid target sequence and a PAM of the second nucleic acid target sequence have an interspacer distance of between 20 base pairs and 42 base pairs.
Cell outside of a human body
The engineered cell is outside of a human body.
The claims focus on a human stem cell engineered with two Class 1 Type I CRISPR-Cas effector complexes built from Cas5 and Cas7 subunits plus Cas8-FokI fusions linked by a linker polypeptide, with guide polynucleotides targeting nucleic acid target sequences whose PAMs have a constrained interspacer distance.
Stated Advantages
Documented Applications
Expression and purification of engineered Type I-E Cascade systems in E. coli and mammalian cells, including promoter-targeting guides for transcriptional activation using a VP64_cpCas7 V2 variant.
Recruitment of Type I Cascade functional subunits using a Type II (dCas9/sgRNA) strategy by incorporating Type I CRISPR repeat stem sequences into Type II guides, with assessment of CXCR4 repression.
Downstream examples for identifying/screening Type I cas genes and crRNAs, probing modifiable crRNA backbone positions, and testing guide-mediated cleavage in human gDNA.
Genome editing support using optimization of FokI-Cas8 and Cas3-FokI combinations for efficient genome editing.
Interested in licensing this patent?